Solution for injections Neo Lasixum is shown at the following indications:

• Hypostases in chronic stagnant heart failure (if treatment using diuretics is necessary).
• Hypostases in acute stagnant heart failure.
• Hypostases in chronic kidney disease.
• Acute renal failure, including at pregnant women or during childbirth.
• Hypostases in liver diseases (in case of need, for addition of treatment using antagonists of Aldosteronum).
• Hypertensive crisis (as the supporting means).
• Support of an artificial diuresis.

Structure

Active ingredient: furosemide;

1 ml of furosemide of 10 mg;

Excipients: sodium hydroxide, sodium chloride, water for injections.

Contraindication

• Hypersensitivity to furosemide or to other components which are a part of medicine. At patients with an allergy to streptocides (for example on sulphonamide antibiotics or sulphonylurea) the cross sensitivity to furosemide can be shown.
• Hypovolemia or dehydration of an organism.
• Renal failure in the form of an anury if the therapeutic answer to furosemide is not observed.
• Renal failure owing to poisoning with nefrotoksichny or gepatotoksichny medicines.
• Heavy gipokaliyemiyeya.
• Heavy hyponatremia.
• Prekomatozny or coma states which are associated with hepatic encephalopathy.

Route of administration

Mode of use is set by the doctor individually depending on expressiveness of disturbances of water and electrolytic balance, size of glomerular filtration, weight of a condition of the patient. In the course of use of medicine it is necessary to adjust indicators of water and electrolytic balance taking into account a diuresis and dynamics of the general condition of the patient.

Furosemide is appointed intravenously only when intake inexpedient or inefficient (for example at disturbance of absorption in intestines) or in case of need fast effect. In case of use of intravenous therapy faster transition to therapy by medicine for oral administration is recommended.

For achievement of optimum efficiency and oppression of counter regulation in general is given preference of continuous infusion of furosemide in comparison with repeated bolyusny injections.

In cases when continuous infusion of furosemide is inexpedient for further treatment after introduction of one or several bolyusny doses, gives preference to the further scheme of treatment with purpose of low doses which are entered through short time intervals (about 4 hours), in comparison with high bolyusny doses, are entered through wide intervals of time.

For adults the recommended maximum daily dose of furosemide of 1500 mg.

For children the recommended furosemide dose for parenteral administration makes 1 mg/kg of body weight, but the maximum daily dose should not exceed 20 mg.

Feature of use

Pregnant

during pregnancy, except for cases of performing treatment according to vital indications.

Children

For children a dose needs to be reduced according to body weight (see the section "Route of Administration and Doses").

Drivers

Should abstain for treatment for control of motor transport or work with other mechanisms.

Overdose

Symptoms: the clinical picture of acute or chronic overdose depends mainly on degree and consequences of loss of electrolytes and liquid and includes such signs as a hypovolemia, organism dehydration, haemo concentration, cardiac arrhythmias (including AV blockade and fibrillation of ventricles). The heavy arterial hypotension (progressing to shock), an acute renal failure, thrombosis, nonsense, a flaccid paralysis, apathy and confusion of consciousness belong to symptoms of these disturbances.

Treatment: there are no specific antidotes of furosemide. Symptomatic therapy.

Side effects

• from organs of hearing and a vestibular mechanism: a hearing disorder which usually is passing, especially at patients with a renal failure, a hypoproteinemia (for example, at a nephrotic syndrome) and/or in case of too fast intravenous administration of furosemide. It was reported about deafness cases, sometimes irreversible, after oral administration or administration of furosemide. A ring in ears.
• from digestive tract: nausea, vomiting, diarrhea, acute pancreatitis.
• from a liver and biliary tract: cholestasia, increase in levels of transaminases.
• from kidneys and an urinary system: tubulo-interstitial nephrite, increase in volume of urine, increase in level of sodium in urine, increase in level of chlorine in urine, an ischuria (at patients with partial obstruction of outflow of urine), a nephrocalcinosis/nephrolithiasis at premature babies, a renal failure.
• from a metabolism, metabolism: disturbances of electrolytic balance (including with clinical manifestations), dehydration and a hypovolemia, especially at patients of advanced age, the hyponatremia, a hypochloraemia, a hypopotassemia, a hypocalcemia, a hypomagnesiemia, a metabolic alkalosis, increase in level of triglycerides in blood, increase in level of cholesterol in blood, increase in level of creatinine in blood, increase in level of uric acid in blood, gout attacks, increase in level of urea in blood, decrease in tolerance to glucose, can pass a course of diabetes from a latent form into expressed, the Barter pseudo-syndrome against the background of the wrong and/or prolonged use of furosemide.
• from nervous system: paresthesias, hepatic encephalopathy at patients with hepatocellular insufficiency.
• from a cardiovascular system: hypotension, including orthostatic hypotension, vasculitis, thrombosis.
• from blood and lymphatic system: haemo concentration, thrombocytopenia, leukopenia, eosinophilia, agranulocytosis, aplastic anemia or hemolytic anemia.
• from the immune system: heavy anaphylactic and anaphylactoid reactions (in particular, followed by shock).
• from skin and hypodermic cellulose: an itching, urticaria, rash, bullous dermatitis, a multiformny erythema, pemphigoid, exfoliative dermatitis, a purpura, reaction of photosensitivity, Stephen-Johnson's syndrome, a toxic epidermal necrolysis, sharp generalizirovanny exanthematous pustulez and DRESS syndrome (a medicamentous rash with an eosinophilia and system symptomatology).
• General disturbances and reactions in the injection site: fervescence, local reactions, for example, pain after an injection.
• Congenital and inherited/genetic disorders: the increased risk of not fusion arterial channels if to appoint furosemide to premature babies during the first days of life.

Interaction

In some cases intake of furosemide within 24 hours after Chlorali hydras can cause inflows, the increased sweating, the excited state, nausea, increase in arterial blood pressure and tachycardia. Therefore simultaneous use of furosemide and Chlorali hydras is not recommended.

Furosemide can increase ototoxicity of aminoglycosides and other ototoksichny medicines. As it can lead to damage that has irreversible character, these medicines should not be applied along with furosemide.

to Store

in original packing at a temperature not above 25 °C.

to Store

out of children's reach.

Expiration date - 3 years.